Active substance
Eprosartan
- SFDA 1
- US FDA 2
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TEVETEN 600MG TAB | 600 mg | Film-coated tablet · Oral use | 28 Blister | SAR 76.50 | NCE · Prescription | ABBOTT BIOLOGICALS | Valid |
Indications — CHI Daman Drug Formulary
CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; HYPERTENSION; SICKLE CELL DISEASE - ALBUMINURIA MANAGEMENT; SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TEVETEN | EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 600MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ABBVIE | Discontinued | 22 Dec 1997 |
| EPROSARTAN MESYLATE | EQ 400MG BASE; EQ 600MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 16 Nov 2011 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Eprosartan 400mg tablets | £26.57 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Eprosartan 600mg tablets | £17.26 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Combinations containing Eprosartan
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.